> Introduction
Company History
- 2016
2008. 06 GM101 phase I clinical trial in Korea
2014. 11 GeneMedicine Co., Ltd., established
2016. 06 Grant Award from KDDF for GM103 development
2016. 07 Licensing Out to USA NASDAQ listed company F
2016. 09 Licensing Out to USA Bio-tech company M
2016. 11 Grant Award from KBIO Health for GM102 development
2017 - 2019
2017. 01 Accredited as bioventure (Kibo)
2018. 04 Accredited as med.-sized business (Ministry of SMEs and Startups)
2018. 12 Received TIPS Grant
2019. 03 Corporate R&D Research Center Accreditation (KOITA)
2019. 05 Series A investment ($13.2 million)
2019. 06 Relocation of office and research space
2019. 07 Grant Award from KDDF for GM103 development
2019. 11 CDMO Contract (WuXi App Tech)
2020 -
2020. 05 Expansion of office and laboratory
2020. 09 Awardee for Bioinnovative Company
2020. 11 Awardee for Innovation Company (Moneytoday)
2020. 12 Commendation from the Minister of Health and Welfare
2021. 06 Selected as Technology Innovation –Oriented Small and Medium Enterprise(Inno-Biz)
2021. 07 Series B Investment ($ 27.2 million)
2021. 10 GMP manufactory construction (Hanam-si : 3,306 sqm)
2022. 06 GMP facilities to be completed - Mfg. starts & CDMO/CMO Biz to be launched in Oct.
2022. 06 Korea Bioprocessing ExcellenceAwards 2022 (Cell & Gene Therapy World East Asia)
